» Articles » PMID: 39118055

Autonomic Neuropathy in Dialysis Patients - Investigations with a New Symptom Score (COMPASS 31)

Overview
Journal BMC Nephrol
Publisher Biomed Central
Specialty Nephrology
Date 2024 Aug 8
PMID 39118055
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Symptoms of autonomic neuropathy (AN) are common in patients with diabetes and advanced renal disease. As yet different domains of autonomic neuropathy cannot be detected by a singular laboratory or invasive test. COMPASS 31, a new self-assessment test, has shown reliable results not only in cardiac autonomic neuropathy but also in different sub-domains when judging manifestation of AN by scores.

Methods: One hundred eighty-three patients with or without diabetes were enrolled, one hundred nineteen of them were treated with permanent dialysis therapy (HD), sixty-four patients served as controls (eGFR > 60 ml/min.) Using COMPASS 31 different symptoms of AN were assessed (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder, pupillomotor changes) and transferred into AN-scores.

Results: AN was more pronounced in dialysis patients compared with controls (AN-score 27,5 vs. 10,0; p < 0,01). These differences were present also in every sub-domain of AN (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder, pupillomotor changes; p < 0,05 for all sub-domains). In diabetic patients there was a strong correlation between symptoms of AN and diabetes duration (correlation coefficient r = 0,45, p < 0,001). Current glycemic control (HbA1c), body mass index (BMI), sex, and height had no influence on AN when comparing dialysis patients and controls. C-reactive protein (CRP) showed a positive linear correlation with AN-scores (correlation coefficient r = 0,21; p < 0,05).

Conclusion: Symptoms of AN are more pronounced in dialysis patients not only in total but also in all different domains of neuropathic changes. Longlasting diabetic disease promotes development of AN, as duration of diabetes was positively correlated with AN. Future longitudinal studies might help to identify the high cardiovascular and mortality risk in dialysis patients by the easy-to-use COMPASS 31 without need of invasive and time-spending methods for diagnosing AN.

Citing Articles

Influence of autonomic neuropathy, systemic inflammation and other clinical parameters on mortality in dialysis patients.

Schramm M, Schramm C, Hoppe J, Trautner M, Hinz M, Mitzner S Clin Kidney J. 2025; 18(2):sfae416.

PMID: 39981139 PMC: 11840246. DOI: 10.1093/ckj/sfae416.

References
1.
Baumgaertel M, Kraemer M, Berlit P . Neurologic complications of acute and chronic renal disease. Handb Clin Neurol. 2013; 119:383-93. DOI: 10.1016/B978-0-7020-4086-3.00024-2. View

2.
Freeman R . Autonomic Peripheral Neuropathy. Continuum (Minneap Minn). 2020; 26(1):58-71. DOI: 10.1212/CON.0000000000000825. View

3.
Sudo S, Montagnoli T, Rocha B, Santos A, de Sa M, Zapata-Sudo G . Diabetes-Induced Cardiac Autonomic Neuropathy: Impact on Heart Function and Prognosis. Biomedicines. 2022; 10(12). PMC: 9775487. DOI: 10.3390/biomedicines10123258. View

4.
Herder C, Bongaerts B, Ouwens D, Rathmann W, Heier M, Carstensen-Kirberg M . Low serum omentin levels in the elderly population with Type 2 diabetes and polyneuropathy. Diabet Med. 2015; 32(11):1479-83. DOI: 10.1111/dme.12761. View

5.
Treister R, ONeil K, Downs H, Oaklander A . Validation of the composite autonomic symptom scale 31 (COMPASS-31) in patients with and without small fiber polyneuropathy. Eur J Neurol. 2015; 22(7):1124-30. PMC: 4464987. DOI: 10.1111/ene.12717. View